Please ensure Javascript is enabled for purposes of website accessibility

Why Atossa Therapeutics Blasted 30% Higher on Monday

By Eric Volkman - Jun 7, 2021 at 6:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company might announce some extremely good news later this week.

What happened

Atossa Therapeutics (ATOS 5.00%) got off to a roaring start this week, with its stock closing just over 30% higher on Monday to reach a new one-year peak. The company announced that clinical results for a promising pipeline drug are coming in a matter of days.

So what

Atossa, a clinical-stage biotech that has been popular with investors of late, said it would publish and discuss final data from the phase 2 study of Endoxifen. This is the company's leading pipeline treatment, a drug that is given to breast cancer patients in advance of surgery. The discussion will take place in a webinar this Wednesday at 8 a.m. PDT; it is to be led by company CEO Steven Quay and other top managers.

A researcher studying a sample in a petri dish.

Image source: Getty Images.

So far, the results of Endoxifen trials disclosed by the company have been very encouraging. In February, Atossa said that the "overwhelmingly positive" results in phase 2 testing in Australia led it to conclude that trial and advance development in the U.S.

Also, a compassionate-use Endoxifen study on one patient spanning over two years showed no recurrence of breast cancer. The drug was well tolerated by the recipient, the company added.

Now what

I should stress that, as ever with biotech stocks, early clinical successes do not guarantee positive results further down the chain. Yet breast cancer is a common disease and effective treatments are sorely needed, so Atossa stock could still have a long runway if Wednesday's news is encouraging. 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Atossa Genetics Inc. Stock Quote
Atossa Genetics Inc.
ATOS
$1.05 (5.00%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.